Methamphetamine anticorps (AbBy Fluor® 594)

N° du produit ABIN2804156

Détail du produit anti-Methamphetamine anticorps (AbBy Fluor® 594)

Antigène: Methamphetamine (M-Amp)

Reactivité: Veuillez nous consulter SVP

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp Methamphetamine est conjugé à/à la AbBy Fluor® 594

Application: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Réactivité croisée (Details): Methamphetamine

Purification: Purified by Protein A.

Immunogène: KLH conjugated to Methamphetamine

Isotype: IgG

Information d'application

Indications d'application: IF(IHC-P) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détails sur Methamphetamine

Antigène: Methamphetamine (M-Amp)

Autre désignation: Methamphetamine (M-Amp Produits)

Classe de substances: Chemical

Sujet:

Synonyms: d-Desoxyephedrine hydrochloride, d-N, -Dimethylphenethylamine hydrochloride, Methylamphetamine hydrochloride.

Background: Methamphetamine (METH) is closely related chemically to amphetamine (AMPH). METH is a potent central nervous system stimulant with additional peripheral sympathomimetic effects. METH and AMPH have been used clinically in the treatment of obesity, minimal brain dysfunction, narcolepsy, depression and to counter fatigue. They are also subjected to widespread abuse. METH is an indirect agonists. It causes the release of newly synthesized norepinephrine and dopamine and it blocks the re uptake of these transmitters from the synapse. This can lead to an increase in the concentration of catecholamines in the synapse as well as an overall increase in catecholaminergic activity in the brain. The mechanism of METH induced neurotoxicity for all monoaminergic cell types may lie primarily with the dopaminergic system in the striatum. It may also lie with the interaction between METH induced release of dopamine and its ability to inhibit monoamine oxidase.